Captain, I think a more interesting question is whether DCVaxL will be approved in conjunction with poly-ICLC and/or Keytruda. Certainly management will include the outstanding results of these two trials with the BLA submission. Yes, and I know the trial with Keytruda is not completed, but it already looks good. I suspect Merck could use some of its clout to push for early approval, if it even needs it since it’s already an approved drug. For that matter, both are approved drugs so both could be used off label. However, both drug makers could benefit from an FDA approval for their drugs to be used in GBM in conjunction with DCVaxL. And perhaps RAs could do that when they approve (IMO) DCVaxL.
Bullish
News 
Market Data 
Discover 
